Joshua Rose

Joshua Rose

Auto-generated profile, based on publicly available information

Joshua Rose

Department of Biochemistry, Duke University School of Medicine, Durham, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2020 in Nature Metabolism
Verified
Journal Article
Open access
PDF file
CDChien-Kuang Cornelia Ding
Chien-Kuang Cornelia Ding
JRJoshua Rose
Joshua Rose
TSTianai Sun
Tianai Sun
JWJianli Wu
Jianli Wu
Po-Han ChenPo-Han Chen
Po-Han Chen
JCJen-Tsan Ashley Chi
Jen-Tsan Ashley Chi
Critical to the bacterial stringent response is the rapid relocation of resources from proliferation toward stress survival through the respective accumulation and degradation of (p)ppGpp by RelA and SpoT homologues. While mammalian genomes encode MESH1, a homologue of the bacterial (p)ppGpp hydrolase SpoT, neither (p)ppGpp nor its synthetase has been identified in mammalian cells. Here, we show that human MESH1 is an efficient cytosolic NADPH phosphatase that facilitates ferroptosis. Visualization of the MESH1–NADPH crystal structure revealed a bona fide affinity for the NADPH substrate. Ferroptosis-inducing erastin or cystine deprivation elevates MESH1, whose overexpression depletes NADPH and sensitizes cells to ferroptosis, whereas MESH1 depletion promotes ferroptosis survival by sustaining the levels of NADPH and GSH and by reducing lipid peroxidation. The ferroptotic protection by MESH1 depletion is ablated by suppression of the cytosolic NAD(H) kinase, NADK, but not its mitochondrial counterpart NADK2. Collectively, these data shed light on the importance of cytosolic NADPH levels and their regulation under ferroptosis-inducing conditions in mammalian cells.

18 November 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
KHKuo-Sheng Hsu
Kuo-Sheng Hsu
JDJames M. Dunleavey
James M. Dunleavey
CSChristopher Szot
Christopher Szot
LYLiping Yang
Liping Yang
MHMary Beth Hilton
Mary Beth Hilton
BCBrad St Croix
Brad St Croix
Collagen I, the most abundant protein in humans, is ubiquitous in solid tumors where it provides a rich source of exploitable metabolic fuel for cancer cells. While tumor cells were unable to exploit collagen directly, here we show they can usurp metabolic byproducts of collagen-consuming tumor-associated stroma. Using genetically engineered mouse models, we discovered that solid tumor growth depends upon collagen binding and uptake mediated by the TEM8/ANTXR1 cell surface protein in tumor-associated stroma. Tumor-associated stromal cells processed collagen into glutamine, which was then released and internalized by cancer cells. Under chronic nutrient starvation, a condition driven by the high metabolic demand of tumors, cancer cells exploited glutamine to survive, an effect that could be reversed by blocking collagen uptake with TEM8 neutralizing antibodies. These studies reveal that cancer cells exploit collagen-consuming stromal cells for survival, exposing an important vulnerability across solid tumors with implications for developing improved anticancer therapy.

21 October 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
JRJoshua Rose
Joshua Rose
HKHyaeyeong Kim
Hyaeyeong Kim
JSJessica Von Stetina
Jessica Von Stetina
MTMahant Thangavelu
Mahant Thangavelu
HCHasahn Conway
Hasahn Conway
JCJesse C Cochrane
Jesse C Cochrane
Many current genome editing technologies rely on the action of large serine integrases (LSIs) to insert gene-sized DNA sequences into the genome. Bxb1 is the most commonly used LSI for therapeutic efforts, including PASTE, PASSIGE and I-PGI. While Bxb1 demonstrated good activity in vitro in cycling cells, the activity in non-dividing hepatocytes was significantly less efficient. Further, wild-type Bxb1 is known to have detectable off-target activity at cryptic genomic sites, which presents a potential safety risk for therapeutic development. To address these issues, we developed Bxb1 variants that demonstrate increased specificity and potency in vitro and have engineered stabilized Bxb1 variants that increase in vivo activity over 25-fold enabling targeted integration at therapeutically relevant levels.

10 April 2026 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
CLChao-Chieh Lin
Chao-Chieh Lin
JRJoshua Rose
Joshua Rose
AZAlbert Zhang
Albert Zhang
AMAnthony J. Mirando
Anthony J. Mirando
AMAlexander A. Mestre
Alexander A. Mestre
JCJen-Tsan Ashley Chi
Jen-Tsan Ashley Chi

2 May 2022
Verified
Conference Paper
Closed access
JRJ.A. Rose
J.A. Rose
AMA.A. Menon
A.A. Menon
THT. Hino
T. Hino
AHAkinori Hata
Akinori Hata
MNM. Nishino
M. Nishino
GHG.M. Hunninghake
G.M. Hunninghake